**PRESS RELEASE**

**Prague, June 23, 2021 – A paper describing clinical utility of Elphogene oncoMonitor® liquid biopsy technology published in Pathology and Oncology Research (Frontiers Media publishing).**

The paper is a result of a 5-year joint project between researchers at Elphogene, Genomac research institute and clinicians at the Faculty Hospital Pilsen. A total of 81 patients with non-small cell lung cancer were followed during the course of the disease treatment over a period of up to 2 years using Elphogene oncoMonitor® liquid biopsy technology. The authors found a tight correlation of the observed dynamic of circulating tumor DNA (ctDNA) with the clinically observed response and suggested using the assay in a routine application for early detection of therapy resistance and disease recurrence.

**

*A waterfall plot showing the treatment benefit in 28 patients according to relative change in ctDNA levels between the start of the first and the end of the second cycle of first-line chemotherapy. PD—progression (red), SD—stabilization (yellow), PR—partial + CR—complete response (green).*